Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113


Isolation and characterization of a Shigella flexneri invasin complex subunit vaccine.

Turbyfill KR, Hartman AB, Oaks EV.

Infect Immun. 2000 Dec;68(12):6624-32.


Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine.

Oaks EV, Turbyfill KR.

Vaccine. 2006 Mar 20;24(13):2290-301. Epub 2005 Dec 5.


Immunogenicity and efficacy of highly purified invasin complex vaccine from Shigella flexneri 2a.

Turbyfill KR, Kaminski RW, Oaks EV.

Vaccine. 2008 Mar 4;26(10):1353-64. doi: 10.1016/j.vaccine.2007.12.040. Epub 2008 Jan 17.


Safety and immunogenicity of an intranasal Shigella flexneri 2a Invaplex 50 vaccine.

Riddle MS, Kaminski RW, Williams C, Porter C, Baqar S, Kordis A, Gilliland T, Lapa J, Coughlin M, Soltis C, Jones E, Saunders J, Keiser PB, Ranallo RT, Gormley R, Nelson M, Turbyfill KR, Tribble D, Oaks EV.

Vaccine. 2011 Sep 16;29(40):7009-19. doi: 10.1016/j.vaccine.2011.07.033. Epub 2011 Jul 23.


Antibody response of monkeys to invasion plasmid antigen D after infection with Shigella spp.

Oaks EV, Picking WD, Picking WL.

Clin Diagn Lab Immunol. 1996 Mar;3(2):242-5.


Evaluation of immunogenicity and protective efficacy of orally delivered Shigella type III secretion system proteins IpaB and IpaD.

Heine SJ, Diaz-McNair J, Martinez-Becerra FJ, Choudhari SP, Clements JD, Picking WL, Pasetti MF.

Vaccine. 2013 Jun 19;31(28):2919-29. doi: 10.1016/j.vaccine.2013.04.045. Epub 2013 May 2.


Safety and immunogenicity of a Shigella flexneri 2a Invaplex 50 intranasal vaccine in adult volunteers.

Tribble D, Kaminski R, Cantrell J, Nelson M, Porter C, Baqar S, Williams C, Arora R, Saunders J, Ananthakrishnan M, Sanders J, Zaucha G, Turbyfill R, Oaks E.

Vaccine. 2010 Aug 23;28(37):6076-85. doi: 10.1016/j.vaccine.2010.06.086. Epub 2010 Jul 7.


Shigella IpaB and IpaD displayed on L. lactis bacterium-like particles induce protective immunity in adult and infant mice.

Heine SJ, Franco-Mahecha OL, Chen X, Choudhari S, Blackwelder WC, van Roosmalen ML, Leenhouts K, Picking WL, Pasetti MF.

Immunol Cell Biol. 2015 Aug;93(7):641-52. doi: 10.1038/icb.2015.24. Epub 2015 Mar 17.


Characterization of a novel fusion protein from IpaB and IpaD of Shigella spp. and its potential as a pan-Shigella vaccine.

Martinez-Becerra FJ, Chen X, Dickenson NE, Choudhari SP, Harrison K, Clements JD, Picking WD, Van De Verg LL, Walker RI, Picking WL.

Infect Immun. 2013 Dec;81(12):4470-7. doi: 10.1128/IAI.00859-13. Epub 2013 Sep 23.


Intradermal delivery of Shigella IpaB and IpaD type III secretion proteins: kinetics of cell recruitment and antigen uptake, mucosal and systemic immunity, and protection across serotypes.

Heine SJ, Diaz-McNair J, Andar AU, Drachenberg CB, van de Verg L, Walker R, Picking WL, Pasetti MF.

J Immunol. 2014 Feb 15;192(4):1630-40. doi: 10.4049/jimmunol.1302743. Epub 2014 Jan 22.


Broadly protective Shigella vaccine based on type III secretion apparatus proteins.

Martinez-Becerra FJ, Kissmann JM, Diaz-McNair J, Choudhari SP, Quick AM, Mellado-Sanchez G, Clements JD, Pasetti MF, Picking WL.

Infect Immun. 2012 Mar;80(3):1222-31. doi: 10.1128/IAI.06174-11. Epub 2011 Dec 27.


Development and preclinical evaluation of a trivalent, formalin-inactivated Shigella whole-cell vaccine.

Kaminski RW, Wu M, Turbyfill KR, Clarkson K, Tai B, Bourgeois AL, Van De Verg LL, Walker RI, Oaks EV.

Clin Vaccine Immunol. 2014 Mar;21(3):366-82. doi: 10.1128/CVI.00683-13. Epub 2014 Jan 8.


Parenteral immunization with IpaB/IpaD protects mice against lethal pulmonary infection by Shigella.

Martinez-Becerra FJ, Scobey M, Harrison K, Choudhari SP, Quick AM, Joshi SB, Middaugh CR, Picking WL.

Vaccine. 2013 May 31;31(24):2667-72. doi: 10.1016/j.vaccine.2013.04.012. Epub 2013 Apr 16.


Identification of epitope and surface-exposed domains of Shigella flexneri invasion plasmid antigen D (IpaD).

Turbyfill KR, Mertz JA, Mallett CP, Oaks EV.

Infect Immun. 1998 May;66(5):1999-2006.


Mucosal adjuvant properties of the Shigella invasin complex.

Kaminski RW, Turbyfill KR, Oaks EV.

Infect Immun. 2006 May;74(5):2856-66.


Multiplexed immunoassay to assess Shigella-specific antibody responses.

Kaminski RW, Clarkson K, Kordis AA, Oaks EV.

J Immunol Methods. 2013 Jul 31;393(1-2):18-29. doi: 10.1016/j.jim.2013.04.002. Epub 2013 Apr 9.


Cloning, expression, and affinity purification of recombinant Shigella flexneri invasion plasmid antigens IpaB and IpaC.

Picking WL, Mertz JA, Marquart ME, Picking WD.

Protein Expr Purif. 1996 Dec;8(4):401-8.


Mucosal adjuvanticity of a Shigella invasin complex with dna-based vaccines.

Kaminski RW, Turbyfill KR, Chao C, Ching WM, Oaks EV.

Clin Vaccine Immunol. 2009 Apr;16(4):574-86. doi: 10.1128/CVI.00435-08. Epub 2009 Feb 18.


Identification and molecular characterization of a 27 kDa Shigella flexneri invasion plasmid antigen, IpaJ.

Buysse JM, Dunyak DS, Hartman AB, Venkatesan MM.

Microb Pathog. 1997 Dec;23(6):357-69.


IpaD of Shigella flexneri is independently required for regulation of Ipa protein secretion and efficient insertion of IpaB and IpaC into host membranes.

Picking WL, Nishioka H, Hearn PD, Baxter MA, Harrington AT, Blocker A, Picking WD.

Infect Immun. 2005 Mar;73(3):1432-40.

Supplemental Content

Support Center